ReP USP - Resultado da busca

Artigo de periodico
Interleukin-8 is not a predictive biomarker for the development of the acute promyelocytic leukemia differentiation syndrome (2020)
Almeida, Luciana Yamamoto de ; Martins, Diego Antonio Pereira ; Lima, Ana Silvia Gouvêa; Baggio, Marcia Sueli; Koury, Luisa Correa de Araujo; Lange, Ana Paula; Bassi, Sarah Cristina; Scheucher, Priscila Santos ; Rego, Eduardo Magalhães
Fonte: Bmc cancer. Unidades: FMRP, FM
Assuntos: LEUCEMIA, INTERLEUCINA 6, INTERLEUCINA 8
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ALMEIDA, Luciana Yamamoto de et al. Interleukin-8 is not a predictive biomarker for the development of the acute promyelocytic leukemia differentiation syndrome. Bmc cancer, v. 20, n. 1, 2020Tradução . . Disponível em: https://doi.org/10.1186/s12885-020-07330-1. Acesso em: 04 nov. 2024.
APA
Almeida, L. Y. de, Martins, D. A. P., Lima, A. S. G., Baggio, M. S., Koury, L. C. de A., Lange, A. P., et al. (2020). Interleukin-8 is not a predictive biomarker for the development of the acute promyelocytic leukemia differentiation syndrome. Bmc cancer, 20( 1). doi:10.1186/s12885-020-07330-1
NLM
Almeida LY de, Martins DAP, Lima ASG, Baggio MS, Koury LC de A, Lange AP, Bassi SC, Scheucher PS, Rego EM. Interleukin-8 is not a predictive biomarker for the development of the acute promyelocytic leukemia differentiation syndrome [Internet]. Bmc cancer. 2020 ; 20( 1):[citado 2024 nov. 04 ] Available from: https://doi.org/10.1186/s12885-020-07330-1
Vancouver
Almeida LY de, Martins DAP, Lima ASG, Baggio MS, Koury LC de A, Lange AP, Bassi SC, Scheucher PS, Rego EM. Interleukin-8 is not a predictive biomarker for the development of the acute promyelocytic leukemia differentiation syndrome [Internet]. Bmc cancer. 2020 ; 20( 1):[citado 2024 nov. 04 ] Available from: https://doi.org/10.1186/s12885-020-07330-1
Artigo de periodico
Risk adapted approach: How to treat splenic marginal zone lymphoma in resource-poor settings? - The real-life experience of a Brazilian cancer treatment center (2020)
Lage, Luis Alberto de Padua Covas; Santos, Felipe Faganelli Caboclo dos; Levy, Debora; Moreira, Frederico Rafael; Couto, Samuel Campanelli Freitas; Culler, Hebert Fabricio; Costa, Renata de Oliveira; Rocha, Vanderson Geraldo ; Pereira, Juliana
Fonte: Bmc cancer. Unidade: FM
Assuntos: ANÁLISE DE VARIÂNCIA, ANTINEOPLÁSICOS, PAÍSES DESENVOLVIDOS, LINFOMA, PROGNÓSTICO, ESTUDOS RETROSPECTIVOS, ESPLENECTOMIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LAGE, Luis Alberto de Padua Covas et al. Risk adapted approach: How to treat splenic marginal zone lymphoma in resource-poor settings? - The real-life experience of a Brazilian cancer treatment center. Bmc cancer, v. 20, n. 1, 2020Tradução . . Disponível em: https://doi.org/10.1186/s12885-020-07204-6. Acesso em: 04 nov. 2024.
APA
Lage, L. A. de P. C., Santos, F. F. C. dos, Levy, D., Moreira, F. R., Couto, S. C. F., Culler, H. F., et al. (2020). Risk adapted approach: How to treat splenic marginal zone lymphoma in resource-poor settings? - The real-life experience of a Brazilian cancer treatment center. Bmc cancer, 20( 1). doi:10.1186/s12885-020-07204-6
NLM
Lage LA de PC, Santos FFC dos, Levy D, Moreira FR, Couto SCF, Culler HF, Costa R de O, Rocha VG, Pereira J. Risk adapted approach: How to treat splenic marginal zone lymphoma in resource-poor settings? - The real-life experience of a Brazilian cancer treatment center [Internet]. Bmc cancer. 2020 ; 20( 1):[citado 2024 nov. 04 ] Available from: https://doi.org/10.1186/s12885-020-07204-6
Vancouver
Lage LA de PC, Santos FFC dos, Levy D, Moreira FR, Couto SCF, Culler HF, Costa R de O, Rocha VG, Pereira J. Risk adapted approach: How to treat splenic marginal zone lymphoma in resource-poor settings? - The real-life experience of a Brazilian cancer treatment center [Internet]. Bmc cancer. 2020 ; 20( 1):[citado 2024 nov. 04 ] Available from: https://doi.org/10.1186/s12885-020-07204-6
Artigo de periodico
Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients (2020)
Gouveia, Gisele Rodrigues ; Ferreira, Suzete C; Siqueira, Sheila A. C; Lage, Luis Alberto de Padua Covas; Hallack Neto, Abrahao E; Costa, Renata de Oliveira; Pereira, Juliana
Fonte: Bmc cancer. Unidade: FM
Assuntos: ENVELHECIMENTO, BIOMARCADORES, MEIA IDADE, ESTUDOS RETROSPECTIVOS, TAXA DE SOBREVIVÊNCIA, LINFOMA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GOUVEIA, Gisele Rodrigues et al. Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients. Bmc cancer, v. 20, n. 1, 2020Tradução . . Disponível em: https://doi.org/10.1186/s12885-020-07553-2. Acesso em: 04 nov. 2024.
APA
Gouveia, G. R., Ferreira, S. C., Siqueira, S. A. C., Lage, L. A. de P. C., Hallack Neto, A. E., Costa, R. de O., & Pereira, J. (2020). Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients. Bmc cancer, 20( 1). doi:10.1186/s12885-020-07553-2
NLM
Gouveia GR, Ferreira SC, Siqueira SAC, Lage LA de PC, Hallack Neto AE, Costa R de O, Pereira J. Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients [Internet]. Bmc cancer. 2020 ; 20( 1):[citado 2024 nov. 04 ] Available from: https://doi.org/10.1186/s12885-020-07553-2
Vancouver
Gouveia GR, Ferreira SC, Siqueira SAC, Lage LA de PC, Hallack Neto AE, Costa R de O, Pereira J. Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients [Internet]. Bmc cancer. 2020 ; 20( 1):[citado 2024 nov. 04 ] Available from: https://doi.org/10.1186/s12885-020-07553-2
Artigo de periodico
Chemoradiotherapy versus chemotherapy as adjuvant treatment for localized gastric cancer: a propensity score-matched analysis (2018)
Girardi, Daniel M; Hoff, Paulo Marcelo G
Fonte: Bmc cancer. Unidade: FM
Assuntos: INSTITUIÇÕES DE SAÚDE, NEOPLASIAS, QUIMIOTERAPIA, EVENTO ADVERSO A MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GIRARDI, Daniel M e HOFF, Paulo Marcelo G. Chemoradiotherapy versus chemotherapy as adjuvant treatment for localized gastric cancer: a propensity score-matched analysis. Bmc cancer, v. 18, 2018Tradução . . Disponível em: https://doi.org/10.1186/s12885-018-4305-x. Acesso em: 04 nov. 2024.
APA
Girardi, D. M., & Hoff, P. M. G. (2018). Chemoradiotherapy versus chemotherapy as adjuvant treatment for localized gastric cancer: a propensity score-matched analysis. Bmc cancer, 18. doi:10.1186/s12885-018-4305-x
NLM
Girardi DM, Hoff PMG. Chemoradiotherapy versus chemotherapy as adjuvant treatment for localized gastric cancer: a propensity score-matched analysis [Internet]. Bmc cancer. 2018 ; 18[citado 2024 nov. 04 ] Available from: https://doi.org/10.1186/s12885-018-4305-x
Vancouver
Girardi DM, Hoff PMG. Chemoradiotherapy versus chemotherapy as adjuvant treatment for localized gastric cancer: a propensity score-matched analysis [Internet]. Bmc cancer. 2018 ; 18[citado 2024 nov. 04 ] Available from: https://doi.org/10.1186/s12885-018-4305-x
Artigo de periodico
Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib (2018)
Fonseca, Leonardo Gomes da; Carrilho, Flair Jose; Hoff, Paulo Marcelo; Marta, Guilherme Nader; Braghiroli, Maria Ignez Freitas Melro; Chagas, Aline Lopes; Sabbaga, Jorge
Fonte: Bmc cancer. Unidade: FM
Assuntos: CARCINOMA HEPATOCELULAR, CITOTOXINAS, INIBIDORES DE ENZIMAS, TAXA DE SOBREVIVÊNCIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FONSECA, Leonardo Gomes da et al. Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib. Bmc cancer, v. 18, 2018Tradução . . Disponível em: https://doi.org/10.1186/s12885-018-5173-0. Acesso em: 04 nov. 2024.
APA
Fonseca, L. G. da, Carrilho, F. J., Hoff, P. M., Marta, G. N., Braghiroli, M. I. F. M., Chagas, A. L., & Sabbaga, J. (2018). Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib. Bmc cancer, 18. doi:10.1186/s12885-018-5173-0
NLM
Fonseca LG da, Carrilho FJ, Hoff PM, Marta GN, Braghiroli MIFM, Chagas AL, Sabbaga J. Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib [Internet]. Bmc cancer. 2018 ; 18[citado 2024 nov. 04 ] Available from: https://doi.org/10.1186/s12885-018-5173-0
Vancouver
Fonseca LG da, Carrilho FJ, Hoff PM, Marta GN, Braghiroli MIFM, Chagas AL, Sabbaga J. Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib [Internet]. Bmc cancer. 2018 ; 18[citado 2024 nov. 04 ] Available from: https://doi.org/10.1186/s12885-018-5173-0
Artigo de periodico
MicroRNA-195 acts as an anti-proliferative miRNA in human melanoma cells by targeting Prohibitin 1 (2017)
Cirilo, Priscila Daniele Ramos; Andrade, Luciana Nogueira de Sousa; Corrêa, Bruna Renata Silva; Qiao, Mei; Furuya, Tatiane Katsue; Chammas, Roger; Penalva, Luiz Otavio Ferraz
Fonte: Bmc cancer. Unidade: FM
Assuntos: MELANOMA, ANTINEOPLÁSICOS, RNA, MICRORNAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CIRILO, Priscila Daniele Ramos et al. MicroRNA-195 acts as an anti-proliferative miRNA in human melanoma cells by targeting Prohibitin 1. Bmc cancer, v. 17, 2017Tradução . . Disponível em: https://doi.org/10.1186/s12885-017-3721-7. Acesso em: 04 nov. 2024.
APA
Cirilo, P. D. R., Andrade, L. N. de S., Corrêa, B. R. S., Qiao, M., Furuya, T. K., Chammas, R., & Penalva, L. O. F. (2017). MicroRNA-195 acts as an anti-proliferative miRNA in human melanoma cells by targeting Prohibitin 1. Bmc cancer, 17. doi:10.1186/s12885-017-3721-7
NLM
Cirilo PDR, Andrade LN de S, Corrêa BRS, Qiao M, Furuya TK, Chammas R, Penalva LOF. MicroRNA-195 acts as an anti-proliferative miRNA in human melanoma cells by targeting Prohibitin 1 [Internet]. Bmc cancer. 2017 ; 17[citado 2024 nov. 04 ] Available from: https://doi.org/10.1186/s12885-017-3721-7
Vancouver
Cirilo PDR, Andrade LN de S, Corrêa BRS, Qiao M, Furuya TK, Chammas R, Penalva LOF. MicroRNA-195 acts as an anti-proliferative miRNA in human melanoma cells by targeting Prohibitin 1 [Internet]. Bmc cancer. 2017 ; 17[citado 2024 nov. 04 ] Available from: https://doi.org/10.1186/s12885-017-3721-7

Unidades USP

ReP

Filtros

Autores

Autores USP

Assuntos

Agência de fomento